Wettbewerb

Regulierung

Schiedsgerichtsbarkeit

Allegra-Dilber-Newsmeldung-web-640x140

Homburger News

Homburger

Zwei neue Counsel für Homburger

Herzlichen Glückwunsch, Allegra Arnold und Dilber Devitre. 
<a href="https://www.homburger.ch/de/home/welcome?utm_source=News-DE&amp;utm_medium=Newsmeldung-DE&amp;utm_campaign=Counsel-24">Zum Porträt</a>

Gesellschaftsrecht / M&A

Immobilien

Steuern

Finanzierungen und Anlageprodukte

Arbeitsrecht und Vergütung für Führungskräfte

IP / IT

Healthcare / Life Sciences

Novartis

Homburger and Novartis

On August 22, 2023, Novartis (SIX: NOVN) announced that it had agreed to transfer its real estate and certain infrastructure-related assets and services pertaining to the Life Science Park Rhine Valley in Stein, Canton of Aargau, Switzerland, to the industrial park operator Getec. Currently, almost 2,000 employees work in pharmaceutical and biotechnology companies on the Life Science Park Rhine Valley.
Upon completion of the transaction, the management and further development of the life science park will be taken over by Getec. The transfer is expected to be completed by the end of 2023 and 25 employees will move from Novartis to Getec.
Homburger advises Novartis alongside Freshfields Bruckhaus Deringer on the Swiss law and tax aspects of the transaction. The Homburger team is led by Daniel Häusermann (Corporate / M&amp;A, Real Estate) and includes Olivier Bühlmann, Daniel Kuhn (both Corporate / M&amp;A, Real Estate), Stefan Gäumann (Real Estate), Oriana Schöni (Corporate / M&amp;A), Reto Heuberger, Peter Müller and Philippe Weber (all Tax), Jürg Frick (Financing and Investment Products), Gregor Bühler and Marc Bircher (both Employment), Andri Hess (IP / IT, Healthcare / Life Sciences), Allegra Arnold and Katharina Bratvogel (both Competition, Regulatory), as well as other professionals.

Homburger advises Novartis on the transfer of the Life Science Park Rhine Valley to Getec

phoenix pharma

Homburger and PHOENIX Pharma Switzerland

After receiving clearance from the Swiss Competition Commission, PHOENIX Pharma Switzerland and the Voigt Group completed the transaction to establish avosano AG, a 50:50 joint venture on April 28, 2023. This closing marks the start of the joint future of Amedis-UE AG, Voigt AG Pharma Grosshandel and Voigt Industrie Service AG under the umbrella of avosano AG. The avosano Group will be an optimally positioned Swiss player in the pharmaceutical wholesale (market share of approx. 35 percent) and prewholesale (market share of approx. 40 percent) with an expected total turnover of approx. CHF 1.7 bn.
Homburger advises PHOENIX Pharma Switzerland on the transaction. The Homburger team is led by Frank Gerhard (Corporate / M&amp;A) and comprises Andreas Burger (Regulatory / Competition) as well as Patrick Schmidt (Corporate / M&amp;A), Allegra Arnold, Daniel Lütolf (both Regulatory / Competition), Angela Casey (Employment), and Fabio Gasser (Corporate / M&amp;A).

Homburger advises PHOENIX Pharma Switzerland on its joint venture with Voigt Group

Allegra
Arnold

Zwei neue Counsel für Homburger

Homburger advises Novartis on the transfer of the Life Science Park Rhine Valley to Getec

Homburger advises PHOENIX Pharma Switzerland on its joint venture with Voigt Group

«Battle for talents»: Arbeitsmarktbezogene Abreden im Schweizer Kartellrecht

The Dominance and Monopolies Review: Switzerland

Merger Control 2019: Switzerland

Join the Team

Allegra Arnold

Karriere

Sprachen

Zulassung

Teams

AllegraArnold

Zwei neue Counsel für Homburger

Homburger advises Novartis on the transfer of the Life Science Park Rhine Valley to Getec

Homburger advises PHOENIX Pharma Switzerland on its joint venture with Voigt Group

«Battle for talents»: Arbeitsmarktbezogene Abreden im Schweizer Kartellrecht

The Dominance and Monopolies Review: Switzerland

Merger Control 2019: Switzerland

Join the Team

Allegra Arnold

Karriere

Sprachen

Zulassung

Teams

Allegra
Arnold